Search | Clinical Trials Finder

Conditions: Phase 1 Pharmacodynamic Study
Interventions: Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Infertility
Interventions: in vitro fertilization (IVF/ICSI); Other
Lead sponsor: New Hope Fertility Center; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Disease
Interventions: Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray; Dietary Supplement · Other · Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Pain
Interventions: OxyCODONE 5 mg Oral Tablet, Oxytocin nasal spray, Placebo Oxycodone, Placebo oxytocin, OxyCODONE 2.5 mg Oral Tablet; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Adult
Interventions: BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers, Bioavailability
Interventions: DSM265 50% SDD granules, DSM265 25% SDD powder for suspension; Drug
Lead sponsor: Medicines for Malaria Venture; Other
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: CC-292, Oral Omeprazole (OMP); Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Headache, Migraine
Interventions: Ketorolac, Prochlorperazine, Diphenhydramine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 17 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stress Response, Mental Stress, Multitasking Behavior and Multitasking Ability, Physiological Stress, Cognitive Symptoms, Motor Activity
Interventions: Cranberry juice, Placebo juice; Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Rhinitis, Allergic, Seasonal
Interventions: fluticasone furoate, fexofenadine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 42
States / cities: Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Rhinitis, Allergic, Perennial
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Migraine
Interventions: Sumatriptan; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Migraine Headaches
Interventions: Rimegepant, Zavegepant; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson Disease
Interventions: PRIM-DJ2727, Placebo oral capsule; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 55 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Hodgkin Lymphoma
Interventions: Entospletinib, Vincristine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Hattiesburg, Mississippi • Charleston, South Carolina

Conditions: Healthy Subjects
Interventions: Polymer based lubricating liquid; Device
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Shoulder Pain, Hiatal Hernia
Interventions: Resteck Shiatsu Neck and Back Massager, Marcaine; Device · Drug
Lead sponsor: Norton Thoracic Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more

Conditions: Safety, and Tolerability
Interventions: DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg; Combination Product · Drug
Lead sponsor: Aspeya Switzerland SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Prednisone, Topical mometasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: Covis Pharma S.à.r.l.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 25
States / cities: Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more

Conditions: Xerostomia, Head and Neck Cancer, Xerostomia Following Radiotherapy
Interventions: Remineralizing Extreme Dry Mouth Spray with Xylitol, Alcohol-Free Moisturizing Dry Mouth Spray; Other · Device
Lead sponsor: Jonas Johnson; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

IVF Clinical Trial of Two Different Treatment Protocols.

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects

Relative Bioavailability Study of CC-292

Intranasal Ketorolac Trial

Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Acute Migraine Treatment in the ED With Gepants

Study of the Fecal Microbiome in Patients With Parkinson's Disease

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy

Pain Relief After Hiatal Hernia Repair Surgery

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Blinded Dry Mouth Spray Crossover Study